Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases

Completed · Phase 1/Phase 2

Conditions studied: Brain Tumor, Brain Metastases

In brief

Purpose: The primary objective of this study is to determine if chemotherapy with carboplatin and temozolomide significantly affects the response rates, or size of disease, in patients with brain metastases, originating from cancer in other parts of the body, compared to patients who have already been treated with radiation. Survival, causes of death, recurrence of disease in the central nervous system, toxicity, and quality of life will all be measured as secondary objective in this study.

Key facts

Study ID

NCT00362817

Run by

Ohio State University Comprehensive Cancer Center

People needed

17

Starts

2004-10-01

Expected to finish

2008-02-01

Last updated by the study team

2017-06-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Pathologically confirmed systemic cancer

You may not qualify if…

• Pregnant
• Known CNS meningeal involvement with cancer

Where it is running

• Ohio State University — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.